Loading...
Market
What will be the market share of Adalimumab-adbm among Humira biosimilars by Dec 31, 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market share reports from pharmaceutical industry analysts and sales data from GoodRx and Boehringer Ingelheim
Story
GoodRx and Boehringer Partner to Offer Humira Biosimilar at Exclusive $550 Price
Jul 18, 2024, 11:03 AM
GoodRx and Boehringer Ingelheim have partnered to launch an exclusive affordability initiative for Adalimumab-adbm, Boehringer's biosimilar to Humira. The initiative sets the price for a two-pack of both high-concentration and low-concentration Adalimumab-adbm at $550, which represents a 92% discount from the original Humira price. This move is aimed at making the biosimilar more accessible to patients who have faced high costs for Humira. The discounted price is expected to make Adalimumab-adbm the lowest-priced version of Humira available in the market. However, questions remain about whether uninsured patients can afford it or find it in a retail pharmacy.
View original story
Similar markets
Amjevita • 25%
Wezlana • 25%
Other • 25%
None • 25%
Humira > Amjevita > Wezlana • 25%
Amjevita > Humira > Wezlana • 25%
Wezlana > Amjevita > Humira • 25%
Other • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10-20% • 25%
21-30% • 25%
More than 30% • 25%
Amgen's Eylea biosimilar • 25%
Regeneron's Eylea • 25%
Novartis biosimilar • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%